FOXO4-DRI
FOXO4-DRI is a senolytic research reagent. Mouse data exist. No human trial exists.
Checked by the PU Research editorial team — evidence-graded against primary sources. Last check: 23 July 2026. Sources: 3. Who checks this
01Identity & Classification
FOXO4-DRI is a D-retro-inverso peptide with about 46 residues. It is a senolytic research reagent.
02Mechanism: How It Works
FOXO4-DRI disrupts the interaction between FOXO4 and p53 through competition. This forces p53 out of the nucleus.
The result is apoptosis that depends on p53 and p21. The effect is selective for senescent cells, because those cells overexpress FOXO4.
03Research Findings
Evidence tier: preclinical only.
Baar et al. (Cell, 2017) reported a decreased senescent-cell burden in mice. The same work reversed doxorubicin chemotoxicity. It improved fur density, kidney function, and activity in naturally aged mice and in progeroid mice.
Later NMR work (Nature Communications, 2025) confirmed binding at the p53 TAD2 site, with a Kd of about 400 nM.
Evidence limit. No human trial exists. An improved analog, CL04183, is still preclinical.
04Reported Dosing & Delivery
No high-authority human dosing exists. It is a research reagent only.
05Pharmacokinetics & Timing
No source specifies the serum half-life. No source specifies the immunogenicity.
07Safety & Contraindications
No human data exist.
08Monitoring & Biomarkers
No validated biomarker exists.
09Regulatory Status
No regulator approves it. It is for research use only. No registered human trial exists. WADA does not name it.
10Works Cited
- 01Baar MP, et al. "Targeted apoptosis of senescent cells...". Cell, 2017. View source →
- 02AACR Cancer Discovery summary.
- 03Nature Communications, 2025 (p53 TAD2 binding). View source →
More in Longevity & Cellular Aging
Open the Longevity category →Epithalon
Epithalon is a synthetic tetrapeptide. The evidence comes largely from one research group and lacks independent replication.
Humanin
Humanin is a mitochondrial-derived peptide. The preclinical record is robust. No interventional human trial exists.
Elamipretide (SS-31)
Elamipretide is a mitochondria-targeted tetrapeptide. The FDA approved it for Barth syndrome in September 2025.
Research use only. This is not medical advice.
PeptideUnlock gives education. Nothing here diagnoses a condition. Nothing here recommends a compound or a dose.
Most peptides on this site have no approval for human use in any country. Some carry documented harms. Several are prohibited in sport.
Regulatory status changes by country and by month. Check the current rule where you live. Speak to a licensed clinician before any health decision.